We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Jacobs (JEC) Awarded EPCM Contract by Aerie Pharmaceuticals
Read MoreHide Full Article
Jacobs Engineering Group Inc. recently secured an engineering, procurement and construction management services (EPCM) contract from Aerie Pharmaceuticals Inc. , for an undisclosed amount.
Over the last month, shares of Jacobs yielded a return of 14.7%, outperforming 11.6% growth recorded by the industry.
This Zacks Rank #3 (Hold) company is poised to grow on the back of diligent business contracts and sound restructuring initiatives. Notably, Jacobs also signed an agreement (on Aug 7, 2017) to acquire CH2M HILL Companies Ltd., which is in sync with its efforts to become a $15-billion global solutions provider over the long run.
Aerie Pharmaceuticals is a clinical-stage pharmaceutical company, focused on the development, discovery and commercialization of premium first-in-class therapies, for treating patients with glaucoma and other eye diseases. The company’s new pharmaceutical manufacturing plant will be located in the Industrial Development Authority’s technology building in Athlone, Republic of Ireland. This facility is being built to commercially process sterile ophthalmic solutions going forward. These solutions will also be sterile filtered, compounded and filled aseptically in the plant.
Leveraging the EPCM expertise for fill-finish facilities, Jacobs will support the design and construction activities of Aerie Pharmaceuticals’ Ireland based pharmaceutical manufacturing plant. Notably, Jacobs will provide further support to Aerie Pharmaceuticals for discovering premium therapies for the treatment of different types of eye diseases going forward.
Jacobs quotes competitive prices for its contracts and ensures that the number of contract receipts increases over time. In the last few months, the company has won a number of contracts from renowned institutions and public-sector agencies like the Chevron Corporation (CVX - Free Report) , Huntington Ingalls
Industries, Inc. (HII - Free Report) , National Aeronautics and Space Administration, and the U.S. Army. Notably, higher transportation spending of the government authorities of Australia, the U.K. and the United States has largely increased Jacobs’ contract winning opportunities in the near term.
More Stock News: This Is Bigger than the iPhone!
It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market.
Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2020.
Image: Bigstock
Jacobs (JEC) Awarded EPCM Contract by Aerie Pharmaceuticals
Jacobs Engineering Group Inc. recently secured an engineering, procurement and construction management services (EPCM) contract from Aerie Pharmaceuticals Inc. , for an undisclosed amount.
Over the last month, shares of Jacobs yielded a return of 14.7%, outperforming 11.6% growth recorded by the industry.
This Zacks Rank #3 (Hold) company is poised to grow on the back of diligent business contracts and sound restructuring initiatives. Notably, Jacobs also signed an agreement (on Aug 7, 2017) to acquire CH2M HILL Companies Ltd., which is in sync with its efforts to become a $15-billion global solutions provider over the long run.
You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Inside Story
Aerie Pharmaceuticals is a clinical-stage pharmaceutical company, focused on the development, discovery and commercialization of premium first-in-class therapies, for treating patients with glaucoma and other eye diseases. The company’s new pharmaceutical manufacturing plant will be located in the Industrial Development Authority’s technology building in Athlone, Republic of Ireland. This facility is being built to commercially process sterile ophthalmic solutions going forward. These solutions will also be sterile filtered, compounded and filled aseptically in the plant.
Leveraging the EPCM expertise for fill-finish facilities, Jacobs will support the design and construction activities of Aerie Pharmaceuticals’ Ireland based pharmaceutical manufacturing plant. Notably, Jacobs will provide further support to Aerie Pharmaceuticals for discovering premium therapies for the treatment of different types of eye diseases going forward.
Jacobs quotes competitive prices for its contracts and ensures that the number of contract receipts increases over time. In the last few months, the company has won a number of contracts from renowned institutions and public-sector agencies like the Chevron Corporation (CVX - Free Report) , Huntington Ingalls
Industries, Inc. (HII - Free Report) , National Aeronautics and Space Administration, and the U.S. Army. Notably, higher transportation spending of the government authorities of Australia, the U.K. and the United States has largely increased Jacobs’ contract winning opportunities in the near term.
More Stock News: This Is Bigger than the iPhone!
It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market.
Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2020.
Click here for the 6 trades >>